Dr. Guy Boivin is a professor in the Department of Microbiology-Immunology and Infectious Diseases of the Faculty of Medicine at Laval University. He holds the Canada Research Chair in Emerging Viruses and Antiviral Resistance, as well as a “Foundation” grant from the Canadian Institutes of Health Research (CIHR). He is also co-principal investigator of major grants, such as the FPQIS ($ 12M), for the development of new generation influenza vaccine in the elderly.

Dr. Boivin is the author or co-author of 300 scientific publications and 350 presentations at various international conferences and symposia. He has also contributed to the creation of 9 patents and is co-founder of the company Signia Therapeutics, specializing in the repositioning of drugs to counter viral respiratory infections. He is also the director of an NC3 laboratory that will be operational in 2018, which will expand the various research projects to highly pathogenic respiratory viruses, such as avian influenza viruses (H5N1, H7N9) and other emerging respiratory viruses. (MERS-CoV).

His research program focuses on the diagnosis, pathogenesis, and treatment of viral infections. He studies herpetic and respiratory viruses, including those causing the flu (including avian flu). More recently, he has also been interested in the Zika virus. He uses cell and molecular biology technologies, as well as different animal models to develop rapid diagnostic tests, evaluate new antiviral molecules, elucidate mechanisms of resistance to antiviral agents, and generate new vaccines. He has developed several multicenter studies to assess the clinical and epidemiological impact of emerging respiratory viruses. He collaborates with several fundamental and clinical research groups as well as various pharmaceutical companies. His work will have a significant impact on the diagnosis, treatment, and prevention of frequent and potentially life-threatening viral infections in certain groups of individuals.

CHUL
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 47762
+1 418-654-2715
guy.boivin@crchudequebec....

Latest news

323 entries « ‹ 1 of 33 › »

Baz M, M'hamdi Z, Carbonneau J, Lavigne S, Couture C, Abed Y, Boivin G

Synergistic PA and HA mutations confer mouse adaptation of a contemporary A/H3N2 influenza virus.

Journal Article

Sci Rep, 9 (1), pp. 16616, 2019, ISSN: 2045-2322.

Abstract | Links:

Dubois J, Pizzorno A, Cavanagh MH, Padey B, Nicolas de Lamballerie C, Uyar O, Venable MC, Carbonneau J, Traversier A, Julien T, Lavigne S, Couture C, Lina B, Hamelin ME, Terrier O, Rosa-Calatrava M, Boivin G

Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development.

Journal Article

Vaccines (Basel), 7 (4), 2019, ISSN: 2076-393X.

Abstract | Links:

Mandon ED, Pizzorno A, Traversier A, Champagne A, Hamelin ME, Lina B, Boivin G, Dejean E, Rosa-Calatrava M, Jawhari A

Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection.

Journal Article

Vaccine, 2019, ISSN: 0264-410X.

Abstract | Links:

Ramendra R, Isnard S, Lin J, Fombuena B, Ouyang J, Mehraj V, Zhang Y, Finkelman M, Costiniuk C, Lebouche B, Chartrand-Lefebvre C, Durand M, Tremblay C, Ancuta P, Boivin G, Routy JP

CMV seropositivity is associated with increased microbial translocation in people living with HIV and uninfected controls.

Journal Article

Clin Infect Dis, 2019, ISSN: 1058-4838.

Abstract | Links:

Abed Y, Fage C, Checkmahomed L, Begin G, Carbonneau J, Lague P, Boivin G

The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors.

Journal Article

Antiviral Res, 170 , pp. 104561, 2019, ISSN: 0166-3542.

Abstract | Links:

Piret J, Schibler M, Pham VD, Hantz S, Giannotti F, Masouridi-Levrat S, Kaiser L, Goyette N, Alain S, Shi R, Boivin G

Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis.

Journal Article

J Infect Dis, 220 (8), pp. 1302-1306, 2019, ISSN: 0022-1899.

Abstract | Links:

Nichols MK, Andrew MK, Ye L, Hatchette TF, Ambrose A, Boivin G, Bowie W, Dos Santos G, Elsherif M, Green K, Haguinet F, Katz K, Leblanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney JE, McGeer A, Powis J, Richardson D, Semret M, Sharma R, Shinde V, Smyth D, Trottier S, Valiquette L, Webster D, McNeil SA, Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research

The Impact of Prior Season Vaccination on Subsequent Influenza Vaccine Effectiveness to Prevent Influenza-related Hospitalizations Over 4 Influenza Seasons in Canada.

Journal Article

Clin Infect Dis, 69 (6), pp. 970-979, 2019, ISSN: 1058-4838.

Abstract | Links:

LeBlanc JJ, ElSherif M, Ye L, MacKinnon-Cameron D, Ambrose A, Hatchette TF, Lang ALS, Gillis HD, Martin I, Demczuk W, Andrew MK, Boivin G, Bowie W, Green K, Johnstone J, Loeb M, McCarthy AE, McGeer A, Semret M, Trottier S, Valiquette L, Webster D, McNeil SA

Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).

Journal Article

Vaccine, 37 (36), pp. 5466-5473, 2019, ISSN: 0264-410X.

Abstract | Links:

Checkmahomed L, M'hamdi Z, Carbonneau J, Venable MC, Baz M, Abed Y, Boivin G

Impact of the baloxavir-resistant polymerase acid (PA) I38T substitution on the fitness of contemporary influenza A(H1N1)pdm09 and A(H3N2) strains.

Journal Article

J Infect Dis, 2019, ISSN: 0022-1899.

Abstract | Links:

Nicolas de Lamballerie C, Pizzorno A, Dubois J, Julien T, Padey B, Bouveret M, Traversier A, Legras-Lachuer C, Lina B, Boivin G, Terrier O, Rosa-Calatrava M

Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia.

Journal Article

Sci Rep, 9 (1), pp. 11493, 2019, ISSN: 2045-2322.

Abstract | Links:

323 entries « ‹ 1 of 33 › »
Signaler des ajouts ou des modifications

Active projects

  • A research program on the pathogenesis, treatment and prevention of respiratory and herpes viruses, Subvention, Instituts de recherche en santé du Canada, Subventions Fondation, from 2016-07-01 to 2023-06-30
  • Canadian Immunization Research Network, Subvention, Instituts de recherche en santé du Canada, Réseau canadien de recherche sur l’immunisation, from 2014-06-01 to 2021-12-31
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche en infectiologie, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2020-04-30
  • Chaire de recherche du Canada sur les virus en émergence et la résistance aux antiviraux, Subvention, Secrétariat des Chaires de recherche du Canada, Chaires de recherche du Canada - Fonctionnement, from 2013-07-01 to 2020-06-30

Recently finished projects

  • (SO04) Severe outcomes of laboratory-confirmed influenza in adults for the 2015-2016 influenza season, Subvention, Instituts de recherche en santé du Canada, Réseau canadien de recherche sur l’immunisation, from 2015-11-01 to 2018-04-30
  • PHAC / CIHR Influenza Research Network, Subvention, Instituts de recherche en santé du Canada, from 2012-06-01 to 2019-03-31
Data provided by the Université Laval research projects registery